Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorAMBA, Mireille Ngale
dc.contributor.authorNTAMBWE, Erick Kamangu
dc.contributor.authorBIONGO, Aline Engo
dc.contributor.authorNTAMABYALIRO, Nsengi
dc.contributor.authorKAHUNU, Gauthier Mesia
dc.contributor.authorMABIALA, Joseph Bodi
dc.contributor.authorNDOSIMAO, Celestin Nsibu
dc.contributor.authorLUTETE, Gaston Tona
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMIREMONT-SALAME, Marie Ghada
ORCID: 0000-0002-6468-8903
IDREF: 153165766
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFOURRIER-REGLAT, Annie
dc.date.accessioned2025-07-08T08:26:51Z
dc.date.available2025-07-08T08:26:51Z
dc.date.issued2025-05-22
dc.identifier.issn2050-6511en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/207255
dc.description.abstractEnINTRODUCTION: Since 2012, DRC adopted WHO recommendations for the malaria treatment with artemisinin-based drugs. Medication errors are defined as "a failure in the treatment process that results in, or has the potential to result in, harm to the patient". Medication errors are a major public health problem and one of the leading causes of death in the United States. The impact of medical errors can have severe consequences on children due to physiological features of children. OBJECTIVES: To identify, describe, and propose actionable strategies to address medication errors during malaria treatment in children with adverse effects in the DRC. METHODS: This is a cross-sectional study of the ADR reports of children (< 18 years old) in the DRC recorded in VigiBase(®), the WHO pharmacovigilance database, from 2010 to February 2018. Five treatment process criteria (choice of treatment, dosage, duration, timing and route of administration) were selected to identify medication errors. RESULTS: Medication errors accounted for 65,9% of the 851 cases retrieved from VigiBase(®). Children aged 2-11 years represented 55.2% of the study population. The choice of treatment, duration and dosage were the main prescription criteria for deviations. DISCUSSION: The availability of alternative formulations, self-medication and inadequate dosage forms are factors contributing to medication errors. The information available in VigiBase(®) did not allow us to evaluate the overall process of malaria management. Pharmacovigilance must be consolidated to raise awareness among consumers and providers and to ensure more effective monitoring. CONCLUSION: Non-compliance with national guidelines for the management of malaria is important in DRC. Our study amply demonstrates the need to strengthen the four pillars of the WHO's third global challenge, "Medication without harm", to reduce medication errors. This study advocates a significant mobilisation of resources for the training of health professionals and the strengthening of pharmacovigilance. Field studies on the management of malaria in children should be conducted to quantify drug errors.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enChildren
dc.subject.enDRC
dc.subject.enMalaria treatment
dc.subject.enMedication errors
dc.subject.enPharmacovigilance
dc.title.enMedication errors in malaria management in children: insights from pharmacovigilance data in the Democratic Republic of Congo
dc.title.alternativeBMC Pharmacol Toxicolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s40360-025-00941-zen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed40405294en_US
bordeaux.journalBMC Pharmacology and Toxicologyen_US
bordeaux.page108en_US
bordeaux.volume26en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05149985
hal.version1
hal.date.transferred2025-07-08T08:26:55Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=BMC%20Pharmacology%20and%20Toxicology&amp;rft.date=2025-05-22&amp;rft.volume=26&amp;rft.issue=1&amp;rft.spage=108&amp;rft.epage=108&amp;rft.eissn=2050-6511&amp;rft.issn=2050-6511&amp;rft.au=AMBA,%20Mireille%20Ngale&amp;NTAMBWE,%20Erick%20Kamangu&amp;BIONGO,%20Aline%20Engo&amp;NTAMABYALIRO,%20Nsengi&amp;KAHUNU,%20Gauthier%20Mesia&amp;rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record